<DOC>
	<DOCNO>NCT02607202</DOCNO>
	<brief_summary>Agnostos Trial multicentric phase 2 randomized trial 'pick-the-winner design ' chemonaive patient cancer unknown primary . It assess efficacy two best active single agent - carboplatin gemcitabine - add innovative taxane back bone ( nab-Paclitaxel ) . Agnostos trial part large clinical translational initiative improve outlook patient cancer unknown primary evaluation novel chemotherapeutic regimen .</brief_summary>
	<brief_title>A Study Nab-paclitaxel-based Doublet First Line Therapy Patients With Cancer Unknown Primary ( CUP )</brief_title>
	<detailed_description>Treatment-naïve patient CUP diagnosis confirm accord CUP Diagnostic Guidelines , enrol AGNOSTOS trial . Patients randomized upfront receive nab-paclitaxel-based duplet add either carboplatin gemcitabine progression unacceptable toxicity ( randomization 1:1 , n= 120 ; 60 per arm ) .</detailed_description>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Provision write informed consent . Patients must ≥ 18 year age . Diagnosis CUP accord CUP Diagnostic Guidelines derive ESMO 2011 NCCN 2015 guideline . Sufficient archive biopsy tissue surgical core needle biopsy require perform CUP multiplex assay . Eastern Cooperative Oncology Group performance status ≤ 2 . No previous systemic therapy . At least one measurable lesion RECIST Criteria . Good liver , cardiac , lung marrow bone function . Evidence nonchildbearing status female patient : negative urine serum pregnancy test within 21 day study treatment woman childbearing potential , postmenopausal status . Patients child bear potential partner , sexually active , must agree use highly effective form contraception throughout participation study . Patient willing able comply protocol duration study , include undergoing treatment schedule visit examination . Patients second primary cancer , except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , breast Ductal Carcinoma Situ ( DCIS ) , stage 1 grade 1 endometrial carcinoma . Specific treatable CUP syndrome include : extragonadal germ cell syndrome ; neuroendocrine carcinoma ; adenocarcinoma isolate axillary lymph node ( woman cancer ) ; peritoneal carcinomatosis ( woman ovarian cancer ) ; squamous carcinoma limit cervical , supraclavicular , inguinal lymph node ; single resectable metastasis . Patients receive radiotherapy ( except palliative reason ) , within 2 week last dose prior study entry . Patients symptomatic uncontrolled brain metastasis . Major surgery within 2 week start study patient must recover effect major surgery . Patients consider poor medical risk due serious , uncontrolled medical disorder , nonmalignant systemic disease active , uncontrolled infection . Examples include , limited , uncontrolled ventricular arrhythmia , recent ( within 6 month ) myocardial infarction , uncontrolled major seizure disorder , unstable spinal cord compression , superior vena cava syndrome , psychiatric disorder prohibits obtain informed consent . Pregnant breast feed woman . Immunocompromised patient , eg , patient know serologically positive human immunodeficiency virus ( HIV ) . Patients know hepatic disease ( eg , Hepatitis B C ) . Previous cancer treatment . Patients currently enrol another clinical tria , except AGNOSTOS PROFILING . Patients receive chemotherapy , hormonal therapy ( HRT acceptable ) novel agent . Patients receive live virus bacterial vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>